Clinical trial
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
Name
FX006-2013-005
Description
The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
Trial arms
Trial start
2013-11-01
Estimated PCD
2014-04-01
Trial end
2014-04-01
Status
Completed
Phase
Early phase I
Treatment
FX006 10 mg
Extended-release formulation
Arms:
FX006 10 mg
FX006 40 mg
Extended-release formulation
Arms:
FX006 40 mg
TCA IR 40 mg
Immediate-release formulation
Arms:
TCA IR 40 mg
Other names:
Kenalog®-40 Injection, Triamcinolone Acetonide Crystalline Suspension (TAcs)
Size
50
Primary endpoint
Concentration of Triamcinolone Acetonide in Synovial Fluid
12 to 20 weeks
Eligibility criteria
Key Inclusion Criteria:
* Written consent to participate in the study
* Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions
* Has documented diagnosis of OA of the index knee made at least 6 months prior to Screening
* Currently meets American Collage of Rheumatology Criteria (clinical and radiological) for OA
* Index knee pain for \>15 days over the last month
* Body mass index (BMI) ≤ 40 kg/m2
* Ambulatory and in good general health
Key Exclusion Criteria:
* History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or amyloidosis
* History of arthritides due to crystals (e.g., gout, pseudogout)
* History of infection in the index joint
* Clinical signs and symptoms of active knee infection or crystal disease of the index knee
* Presence of surgical hardware or other foreign body in the index knee
* Unstable joint (such as a torn anterior cruciate ligament) within 12 months of Screening
* IA corticosteroid (investigational or marketed) in any joint within 6 months of Screening
* IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening
* Oral corticosteroids (investigational or marketed) within 1 month of Screening
* Inhaled, intranasal and topical corticosteroids (investigational or marketed) within 2 weeks of Screening
* Any other IA investigational drug/biologic within 6 months of Screening
* Prior use of FX006
* Prior arthroscopic or open surgery of the index knee within 12 months of Screening
* Planned/anticipated surgery of the index knee during the study period
* Active or history of malignancy within the last 5 years, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 50, 'type': 'ACTUAL'}}
Updated at
2024-01-24
1 organization
4 products
1 indication
Organization
Pacira PharmaceuticalsProduct
FX006Indication
Osteoarthritis of the KneeProduct
TCA IRProduct
TCA IR 40Product
TCA IR 40 mg